Benzinga · Sep 22, 2026
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Oppenheimer analyst Mazahir Alimohamed reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and lowers the price target from $50 to $40.
NASDAQ · TYRA
Tyra Biosciences, Inc.
Healthcare · Biotechnology
$20.43
Down-$0.58 (-2.76%)
Updated Oct 3, 2026, 11:10 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.22B
- P/E ratio
- -12.83
- Dividend yield
- 0.00%
- 52-week range
- $13.29 – $40.65
- Volume
- 1.05M
- Avg. volume
- 330.86K
Price performance · TYRA
TYRA price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
TYRA closed at $20.43 after 20 trading sessions, down 28.69% for the selected period.
- Last close
- $20.43
- Period change
- -28.69%
- Period low
- $20.43
- Period high
- $28.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $21.25 | $21.385 | $20.17 | $20.43 | 1.05M |
| Oct 1, 2026 | $21.78 | $22.315 | $20.88 | $21.01 | 889.7K |
| Sep 30, 2026 | $22.19 | $22.45 | $21.70 | $21.87 | 1.03M |
| Sep 29, 2026 | $21.37 | $22.62 | $21.285 | $21.98 | 501.8K |
| Sep 28, 2026 | $21.57 | $21.925 | $21.00 | $21.45 | 824.58K |
| Sep 25, 2026 | $22.33 | $22.41 | $21.665 | $21.76 | 1.42M |
| Sep 24, 2026 | $23.17 | $23.405 | $22.12 | $22.41 | 1.09M |
| Sep 23, 2026 | $25.27 | $25.39 | $22.8601 | $23.23 | 1.1M |
| Sep 22, 2026 | $25.77 | $26.43 | $25.20 | $25.57 | 1.22M |
| Sep 21, 2026 | $26.04 | $26.96 | $25.395 | $25.65 | 989.22K |
| Sep 18, 2026 | $24.58 | $25.88 | $24.40 | $25.73 | 2.07M |
| Sep 17, 2026 | $24.80 | $25.17 | $24.265 | $24.43 | 511.83K |
| Sep 16, 2026 | $25.58 | $26.15 | $24.15 | $24.35 | 1.14M |
| Sep 15, 2026 | $24.71 | $25.775 | $24.15 | $25.43 | 1.14M |
| Sep 14, 2026 | $23.20 | $26.36 | $23.20 | $25.07 | 2.07M |
| Sep 11, 2026 | $23.63 | $23.96 | $21.86 | $22.03 | 1.55M |
| Sep 10, 2026 | $21.41 | $23.64 | $21.2744 | $23.54 | 2.48M |
| Sep 9, 2026 | $18.94 | $22.3018 | $18.66 | $22.01 | 6.07M |
| Sep 8, 2026 | $27.95 | $29.49 | $26.70 | $26.73 | 1.16M |
| Sep 4, 2026 | $24.51 | $29.56 | $24.51 | $28.65 | 1.86M |
Latest TYRA news
The latest Smart Investors Daily articles mentioning TYRA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TYRA research
Overview
Company profile and research snapshot.
Company profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $36.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 22, 2026 | Oppenheimer | Outperform | — |
| Sep 10, 2026 | Wedbush | Outperform | — |
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 4, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 22, 2026
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $30 to $29.
Yahoo · Sep 16, 2026
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor. The study enrolled patients with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At the August 31, 2026 cutoff, 14 participants receiving 60 mg once daily had received treatment and completed at least the three-month disease assessment, […]
Yahoo · Sep 16, 2026
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value. With the stock resetting after mixed bladder cancer drug data and a sizeable equity offering, the question is how closely that current market price lines up with the assets on its balance sheet. Over the past year, Tyra Biosciences has gained about 105.7%, which raises the issue of whether that move...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
